Patents by Inventor Tianfeng Xu

Tianfeng Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANDROGEN RECEPTOR PROTEIN DEGRADERS WITH A TRICYCLIC CEREBLON LIGAND
    Publication number: 20230357249
    Abstract: The present disclosure provides compounds represented by Formula I : A-L-B 1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification, ompounds having Formula I are androgen receptor degraders useful for the treatment of ancer and other diseases.
    Type: Application
    Filed: May 14, 2021
    Publication date: November 9, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao, Mingliang Wang, Rohan Rej
  • SMALL MOLECULE ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20230257365
    Abstract: The present disclosure provides compounds represented by Formula I: A-L-B1 I, and the salts or solvates thereof, wherein A, L, and B1 are as defined in the specification. Compounds having Formula I are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: August 17, 2023
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Chong Qin, Tianfeng Xu, Lijie Zhao
  • CEREBLON E3 LIGASE INHIBITORS
    Publication number: 20220388978
    Abstract: The present disclosure provides compounds represented by Formula I: wherein R2a, R2b, R2c, R2d, R3, R13, and Z are as defined in the specification, and the salts and solvates thereof. Compounds of Formula I are cereblon (CRBN) ubiquitination inhibitors or monofunctional synthetic intermediates that can be used to prepare PROTAC molecules. CRBN ubiquitination inhibitors and PROTAC molecules are useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: August 27, 2020
    Publication date: December 8, 2022
    Inventors: Shaomeng Wang, Tianfeng Xu, Mingliang Wang, Jiantao Hu, Xi Han, Weiguo Xiang, Rohan Rej
  • SPIROCYCLIC ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220380368
    Abstract: The present disclosure provides compounds represented by Formula (I) and the salts or solvates thereof, wherein R3a, E, L, A1, B1, X1, X2, Z1, and Z2 are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer and other diseases.
    Type: Application
    Filed: September 18, 2020
    Publication date: December 1, 2022
    Inventors: Shaomeng Wang, Xin Han, Weiguo Xiang, Bukeyan Miao, Chong Qin, Lijie Zhao, Jianfeng Lu, Tianfeng Xu, Chao-Yie Yang
  • ANDROGEN RECEPTOR PROTEIN DEGRADERS
    Publication number: 20220081435
    Abstract: The present disclosure provides compounds represented by Formula (I): A-L-B (I), and the salts or solvates thereof, wherein A, L, and B are as defined in the specification. Compounds having Formula (I) are androgen receptor degraders useful for the treatment of cancer.
    Type: Application
    Filed: December 19, 2019
    Publication date: March 17, 2022
    Inventors: Shaomeng Wang, Xin Han, Chao Wang, Chong Qin, Weiguo Xiang, Tianfeng Xu, Chao-Yie Yang
  • SMALL MOLECULE MENIN INHIBITORS
    Publication number: 20210353610
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R1a, R1b, R1c, E, G, and Q are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat cancer or any other disease, condition, or disorder that is responsive to inhibition of menin.
    Type: Application
    Filed: September 30, 2019
    Publication date: November 18, 2021
    Inventors: Shaomeng WANG, Shilin XU, Angelo AGUILAR, Liyue HUANG, Tianfeng XU, Meng ZHANG, Renqi XU, Fuming XU, Haibin ZHOU, Tao LIU
  • PIPERIDINES AS MENIN INHIBITORS
    Publication number: 20210198237
    Abstract: The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: November 23, 2020
    Publication date: July 1, 2021
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • Piperidines as covalent menin inhibitors
    Patent number: 11045448
    Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: March 30, 2018
    Date of Patent: June 29, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Shilin Xu, Liyue Huang, Jeanne Stuckey, Tianfeng Xu
  • Piperidines as menin inhibitors
    Patent number: 10899738
    Abstract: The present disclosure provides compounds by Formula (I): (Formula (I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Grant
    Filed: May 2, 2017
    Date of Patent: January 26, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang
  • PIPERIDINES AS COVALENT MENIN INHIBITORS
    Publication number: 20200022953
    Abstract: The present disclosure provides compounds represented by Formula (I): and the pharmaceutically acceptable salts and solvates thereof, wherein A, R1a, R1b, R1c, R1d, R2, R3, R8a, R8b, R10, X, Z2, m, and n are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: March 30, 2018
    Publication date: January 23, 2020
    Inventors: Shaomeng Wang, Angelo Aguilar, Shilin Xu, Liyue Huang, Jeanne Stuckey, Tianfeng Xu
  • PIPERIDINES AS MENIN INHIBITORS
    Publication number: 20190152947
    Abstract: The present disclosure provides compounds by Formula (I): (Formula(I)) and the pharmaceutically acceptable salts, hydrates, and solvates thereof, wherein R2, R3a, R3b, A, G, X, and Y are as defined as set forth in the specification. The present disclosure also provides compounds of Formula (I) for use to treat a condition or disorder responsive to menin inhibition such as cancer.
    Type: Application
    Filed: May 2, 2017
    Publication date: May 23, 2019
    Inventors: Shaomeng Wang, Angelo Aguilar, Ke Zheng, Shilin Xu, Tianfeng Xu, Denzil Bernard, Liyue Huang